United States-based QuVa Pharma Inc has confirmed its ability to offer Dexamethasone Phosphate as a compounded sterile product in a ready-to-administer IV bag to treat hospitalised COVID-19 patients, in accordance with the FDA Drug Shortage guidelines, it was reported on Thursday.
The company's Dexamethasone Phosphate is a compounded sterile product (CSP) available as 6mg in 25ml 0.9% sodium chloride IV bag and is now available to be ordered.
Stuart Hinchen, co-founder and chief executive officer at QuVa, said, 'Dexamethasone phosphate has been listed on FDA's Drug Shortages list, as well as their list of compounded drugs for hospitalised COVID-19 patients. QuVa is committed to supporting hospitals as they advance quality patient care, and a ready-to-administer intravenous presentation will enable hospitals to meet their patient care needs while their pharmaceutical supply chain for this product improves.'
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma